Pyrotinib

• Description :

  Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].

• Product Name Alternative :

  SHR-1258

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Pyrotinib.html

• Purity :

  99.89

• Solubility :

  0.1 M Maleic Acid : 16.67 mg/mL (ultrasonic) |1 M Maleic Acid : 100 mg/mL (ultrasonic) |DMSO : 10 mg/mL (ultrasonic; adjust pH to 6 with HCl)

• Smiles :

  O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5

• Molecular Formula :

  C32H31ClN6O3

• Molecular Weight :

  583.08

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987 (17) 30043-X.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2

• Citation 01 :

  Biomed Pharmacother. 2024 Nov:180:117523.|Biosci Rep. 2020 Feb 28;40 (2) :BSR20194167.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Clin Transl Oncol. 2024 May 25.|Int J Biol Macromol. 2023 Jul 1;242 (Pt 2) :124870.|iScience. 2024 Jan 9;27 (2) :108839.|J Exp Clin Cancer Res. 2025 Aug 19;44 (1) :245.|J Med Chem. 2019 May 9;62 (9) :4772-4778.|J Thorac Oncol. 2024 Jan;19 (1) :106-118.|Lung Cancer. 2018 Dec:126:72-79.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2025 Jul;6 (7) :1202-1222.|Patent. US 20220175778A1.|Patent. US20210361655A1.|Patent. US20250312348A1.|STAR Protoc. 2024 Apr 16;5 (2) :102987.|Int J Cancer. 2024 Jul 15;155 (2) :324-338.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.

• CAS Number :

  [1269662-73-8]